Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa subretinal DVC1-0401 gene therapy trial in retinitis pigmentosa
jRCT2073180024Phase 1Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2019
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DVC1-0401 in retinitis pigmentosa (RP), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Incidence of adverse events. Started May 2019; status: completed.
02
Drugs
DVC1-0401
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on jRCT2073180024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2073180024.